Share Price and Basic Stock Data
Last Updated: December 17, 2025, 11:19 pm
| PEG Ratio | 0.00 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Decipher Labs Ltd operates within the pharmaceuticals sector, a field that has seen tremendous evolution and competition. In recent years, the company’s revenue trajectory has been less than stellar. For instance, sales stood at ₹45.57 Cr for FY 2023, a significant drop from ₹65.32 Cr in FY 2022. This decline reflects a broader trend of decreasing sales, with the latest quarterly figures showing a dip to ₹7.49 Cr in September 2023, down from ₹9.51 Cr in June 2023. The company has faced challenges in maintaining its market position, which is evident from the fluctuating sales figures across quarters. The trailing twelve months (TTM) revenue now rests at ₹18.09 Cr, indicating ongoing struggles in achieving consistent growth. The revenue per share also declined sharply, which poses concerns about the company’s ability to generate sustainable income moving forward.
Profitability and Efficiency Metrics
Profitability remains a significant concern for Decipher Labs. The company reported an operating profit margin (OPM) of -113.70% for the latest quarter, a stark contrast to the positive margins seen in previous years. This negative margin signifies that operational costs are outpacing revenues alarmingly. The net profit stood at -₹9.46 Cr, translating to an earnings per share (EPS) of -₹5.03 for FY 2025, down from a profitable ₹11.27 in FY 2022. Efficiency metrics, such as the cash conversion cycle (CCC), have also shown a deterioration, with CCC now at 68.12 days, indicating that the company is taking longer to convert its investments into cash flow. Such figures raise red flags about operational efficiency and raise questions about the company’s ability to manage its costs effectively while navigating through a challenging market environment.
Balance Sheet Strength and Financial Ratios
Turning to Decipher Labs’ balance sheet, the company appears to be in a relatively comfortable position concerning its borrowings, with total borrowings reported at just ₹0.43 Cr. This low debt level suggests that the company is not overly leveraged, which is a positive aspect. However, the reserves of ₹9.04 Cr indicate limited buffer capacity to absorb losses or invest in growth initiatives. The price-to-book value ratio stands at 0.46x, suggesting that the stock is trading at a discount to its book value, which may appeal to value investors. Yet, the return on equity (ROE) of 1.16% and return on capital employed (ROCE) of 4.67% reveal that the company is struggling to generate adequate returns on its investments. These ratios could deter potential investors, as they reflect inefficiency in utilizing shareholder funds and capital.
Shareholding Pattern and Investor Confidence
The shareholding structure of Decipher Labs shows a predominance of public shareholders, owning 83.57% of the equity, with promoters holding a mere 16.43%. This distribution indicates a lack of strong insider confidence in the company’s future prospects. The number of shareholders has also declined from 40,027 in December 2022 to 30,174 as of September 2025, suggesting waning interest among retail investors. Such a trend could be a red flag for potential investors, as a declining shareholder base may reflect dissatisfaction with the company’s performance. Furthermore, the absence of institutional investors (FIIs and DIIs) indicates a lack of interest from larger, more experienced market players, which could further undermine investor confidence in the stock.
Outlook, Risks, and Final Insight
Looking ahead, Decipher Labs faces significant challenges that could impact its future performance. The company’s declining sales and profitability metrics raise concerns about its operational strategy and market positioning. While the low debt levels provide some cushion, the lack of growth in reserves and the negative profitability margins are troubling. Investors should be cautious, as the current trends suggest a potential risk of further declines in shareholder value. On the flip side, if the company can successfully implement effective cost management strategies and rejuvenate its product offerings, there could be a turnaround. However, the path to recovery appears steep, and investors would be wise to monitor developments closely, particularly in terms of operational efficiency and market demand for its products. In this competitive landscape, the company’s next moves will be crucial in determining whether it can regain investor confidence and return to a growth trajectory.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Lactose (India) Ltd | 146 Cr. | 116 | 235/84.3 | 32.3 | 49.6 | 0.00 % | 12.9 % | 9.69 % | 10.0 |
| MPS Pharmaa Ltd | 3.38 Cr. | 1.77 | 4.33/1.76 | 0.33 | 0.00 % | 9.79 % | 59.0 % | 10.0 | |
| Gujarat Themis Biosyn Ltd | 4,189 Cr. | 384 | 479/192 | 86.7 | 24.3 | 0.17 % | 27.3 % | 21.7 % | 1.00 |
| Gujarat Terce Laboratories Ltd | 32.0 Cr. | 43.1 | 92.2/37.2 | 10.6 | 0.00 % | 41.4 % | 14.6 % | 10.0 | |
| Gujarat Inject (Kerala) Ltd | 46.3 Cr. | 31.6 | 32.0/17.0 | 110 | 6.93 | 0.00 % | 13.5 % | 11.0 % | 10.0 |
| Industry Average | 20,299.02 Cr | 1,144.49 | 51.46 | 202.18 | 0.36% | 16.29% | 15.20% | 6.10 |
Quarterly Result
| Metric | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 12.62 | 12.12 | 11.06 | 9.78 | 9.51 | 7.49 | 8.29 | 10.59 | 7.44 | 5.87 | 5.80 | 3.50 | 2.92 |
| Expenses | 13.36 | 12.98 | 14.02 | 13.63 | 9.65 | 9.66 | 8.16 | 9.38 | 6.13 | 7.20 | 6.43 | 10.08 | 6.24 |
| Operating Profit | -0.74 | -0.86 | -2.96 | -3.85 | -0.14 | -2.17 | 0.13 | 1.21 | 1.31 | -1.33 | -0.63 | -6.58 | -3.32 |
| OPM % | -5.86% | -7.10% | -26.76% | -39.37% | -1.47% | -28.97% | 1.57% | 11.43% | 17.61% | -22.66% | -10.86% | -188.00% | -113.70% |
| Other Income | 6.86 | 2.66 | -4.55 | 0.15 | 0.01 | 0.14 | 0.00 | 0.27 | 0.16 | 0.12 | 0.17 | 0.87 | 0.01 |
| Interest | 0.11 | 0.12 | 0.13 | 0.07 | 0.01 | 0.00 | 0.00 | 0.21 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation | 0.10 | 0.10 | 0.11 | 0.12 | 0.11 | 0.11 | 0.12 | 0.11 | 0.11 | 0.12 | 0.12 | 0.13 | 0.12 |
| Profit before tax | 5.91 | 1.58 | -7.75 | -3.89 | -0.25 | -2.14 | 0.01 | 1.16 | 1.36 | -1.33 | -0.58 | -5.84 | -3.43 |
| Tax % | 0.00% | 24.05% | 0.13% | 9.77% | 280.00% | -9.35% | 0.00% | -3.45% | 30.15% | 0.00% | 1.72% | -29.62% | 0.00% |
| Net Profit | 5.91 | 1.19 | -7.75 | -4.27 | -0.95 | -1.94 | 0.01 | 1.20 | 0.95 | -1.33 | -0.59 | -4.11 | -3.43 |
| EPS in Rs | 5.85 | 1.18 | -7.67 | -4.23 | -0.94 | -1.92 | 0.01 | 1.19 | 0.94 | -1.32 | -0.58 | -4.07 | -3.40 |
Last Updated: August 19, 2025, 8:20 pm
Below is a detailed analysis of the quarterly data for Decipher Labs Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:
- For Sales, as of Jun 2025, the value is 2.92 Cr.. The value appears to be declining and may need further review. It has decreased from 3.50 Cr. (Mar 2025) to 2.92 Cr., marking a decrease of 0.58 Cr..
- For Expenses, as of Jun 2025, the value is 6.24 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 10.08 Cr. (Mar 2025) to 6.24 Cr., marking a decrease of 3.84 Cr..
- For Operating Profit, as of Jun 2025, the value is -3.32 Cr.. The value appears strong and on an upward trend. It has increased from -6.58 Cr. (Mar 2025) to -3.32 Cr., marking an increase of 3.26 Cr..
- For OPM %, as of Jun 2025, the value is -113.70%. The value appears strong and on an upward trend. It has increased from -188.00% (Mar 2025) to -113.70%, marking an increase of 74.30%.
- For Other Income, as of Jun 2025, the value is 0.01 Cr.. The value appears to be declining and may need further review. It has decreased from 0.87 Cr. (Mar 2025) to 0.01 Cr., marking a decrease of 0.86 Cr..
- For Interest, as of Jun 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Depreciation, as of Jun 2025, the value is 0.12 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 0.13 Cr. (Mar 2025) to 0.12 Cr., marking a decrease of 0.01 Cr..
- For Profit before tax, as of Jun 2025, the value is -3.43 Cr.. The value appears strong and on an upward trend. It has increased from -5.84 Cr. (Mar 2025) to -3.43 Cr., marking an increase of 2.41 Cr..
- For Tax %, as of Jun 2025, the value is 0.00%. The value appears to be increasing, which may not be favorable. It has increased from -29.62% (Mar 2025) to 0.00%, marking an increase of 29.62%.
- For Net Profit, as of Jun 2025, the value is -3.43 Cr.. The value appears strong and on an upward trend. It has increased from -4.11 Cr. (Mar 2025) to -3.43 Cr., marking an increase of 0.68 Cr..
- For EPS in Rs, as of Jun 2025, the value is -3.40. The value appears strong and on an upward trend. It has increased from -4.07 (Mar 2025) to -3.40, marking an increase of 0.67.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: December 15, 2025, 3:52 am
| Metric | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| Sales | 1.02 | 8.06 | 23.99 | 55.56 | 65.32 | 45.57 | 35.88 | 22.61 | 16.53 |
| Expenses | 0.95 | 7.61 | 21.47 | 52.08 | 59.29 | 49.74 | 36.56 | 24.50 | 26.94 |
| Operating Profit | 0.07 | 0.45 | 2.52 | 3.48 | 6.03 | -4.17 | -0.68 | -1.89 | -10.41 |
| OPM % | 6.86% | 5.58% | 10.50% | 6.26% | 9.23% | -9.15% | -1.90% | -8.36% | -62.98% |
| Other Income | 0.11 | 0.00 | 0.27 | 0.65 | 7.67 | 0.92 | 0.16 | -4.02 | 1.07 |
| Interest | 0.00 | 0.01 | 0.77 | 1.17 | 0.48 | 0.48 | 0.24 | 0.00 | 0.00 |
| Depreciation | 0.00 | 0.00 | 0.56 | 0.82 | 0.87 | 0.43 | 0.45 | 0.48 | 0.50 |
| Profit before tax | 0.18 | 0.44 | 1.46 | 2.14 | 12.35 | -4.16 | -1.21 | -6.39 | -9.84 |
| Tax % | 0.00% | 9.09% | 25.34% | 34.58% | 7.85% | -35.58% | 38.02% | -20.50% | |
| Net Profit | 0.18 | 0.41 | 1.10 | 1.40 | 11.38 | -2.68 | -1.68 | -5.08 | -8.11 |
| EPS in Rs | 0.22 | 0.51 | 1.09 | 1.39 | 11.27 | -2.65 | -1.66 | -5.03 | -8.03 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
YoY Net Profit Growth
| Year | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 127.78% | 168.29% | 27.27% | 712.86% | -123.55% | 37.31% | -202.38% |
| Change in YoY Net Profit Growth (%) | 0.00% | 40.51% | -141.02% | 685.58% | -836.41% | 160.86% | -239.69% |
Decipher Labs Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 7 years from 2018-2019 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | -1% |
| 3 Years: | -30% |
| TTM: | -47% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | -4400% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 4% |
| 5 Years: | -15% |
| 3 Years: | -39% |
| 1 Year: | -41% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | 10% |
| 3 Years: | -4% |
| Last Year: | -23% |
Last Updated: September 5, 2025, 3:11 pm
Balance Sheet
Last Updated: December 4, 2025, 2:43 am
| Month | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 8.00 | 8.00 | 10.10 | 10.10 | 10.10 | 10.10 | 10.10 | 10.10 | 10.10 |
| Reserves | -5.88 | -5.47 | 2.46 | 3.59 | 14.07 | 13.11 | 11.76 | 12.76 | 9.04 |
| Borrowings | 0.13 | 0.20 | 11.28 | 16.39 | 10.32 | 0.95 | 0.00 | 0.24 | 0.43 |
| Other Liabilities | 0.71 | 3.61 | 11.55 | 8.64 | 7.46 | 4.01 | 11.77 | 2.66 | 4.19 |
| Total Liabilities | 2.96 | 6.34 | 35.39 | 38.72 | 41.95 | 28.17 | 33.63 | 25.76 | 23.76 |
| Fixed Assets | 0.00 | 0.01 | 4.98 | 4.43 | 2.83 | 3.31 | 2.91 | 2.54 | 2.67 |
| CWIP | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.26 | 3.76 | 3.39 | 0.26 | 0.00 |
| Other Assets | 2.96 | 6.33 | 30.41 | 34.29 | 38.86 | 21.10 | 27.33 | 22.96 | 21.09 |
| Total Assets | 2.96 | 6.34 | 35.39 | 38.72 | 41.95 | 28.17 | 33.63 | 25.76 | 23.76 |
Below is a detailed analysis of the balance sheet data for Decipher Labs Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 10.10 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 10.10 Cr..
- For Reserves, as of Sep 2025, the value is 9.04 Cr.. The value appears to be declining and may need further review. It has decreased from 12.76 Cr. (Mar 2025) to 9.04 Cr., marking a decrease of 3.72 Cr..
- For Borrowings, as of Sep 2025, the value is 0.43 Cr.. The value appears to be increasing, which may not be favorable. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has increased from 0.24 Cr. (Mar 2025) to 0.43 Cr., marking an increase of 0.19 Cr..
- For Other Liabilities, as of Sep 2025, the value is 4.19 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 2.66 Cr. (Mar 2025) to 4.19 Cr., marking an increase of 1.53 Cr..
- For Total Liabilities, as of Sep 2025, the value is 23.76 Cr.. The value appears to be improving (decreasing). It has decreased from 25.76 Cr. (Mar 2025) to 23.76 Cr., marking a decrease of 2.00 Cr..
- For Fixed Assets, as of Sep 2025, the value is 2.67 Cr.. The value appears strong and on an upward trend. It has increased from 2.54 Cr. (Mar 2025) to 2.67 Cr., marking an increase of 0.13 Cr..
- For CWIP, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Investments, as of Sep 2025, the value is 0.00 Cr.. The value appears to be declining and may need further review. It has decreased from 0.26 Cr. (Mar 2025) to 0.00 Cr., marking a decrease of 0.26 Cr..
- For Other Assets, as of Sep 2025, the value is 21.09 Cr.. The value appears to be declining and may need further review. It has decreased from 22.96 Cr. (Mar 2025) to 21.09 Cr., marking a decrease of 1.87 Cr..
- For Total Assets, as of Sep 2025, the value is 23.76 Cr.. The value appears to be declining and may need further review. It has decreased from 25.76 Cr. (Mar 2025) to 23.76 Cr., marking a decrease of 2.00 Cr..
Notably, the Reserves (9.04 Cr.) exceed the Borrowings (0.43 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow
| Month | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|
Free Cash Flow
| Month | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | -0.06 | 0.25 | -8.76 | -12.91 | -4.29 | -5.12 | -0.68 | -2.13 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|
| Debtor Days | 211.13 | 156.69 | 222.44 | 76.67 | 71.47 | 78.90 | 79.35 | 68.12 |
| Inventory Days | 91.25 | 19.70 | 0.00 | |||||
| Days Payable | 511.00 | 192.66 | ||||||
| Cash Conversion Cycle | -208.62 | -16.27 | 222.44 | 76.67 | 71.47 | 78.90 | 79.35 | 68.12 |
| Working Capital Days | 751.47 | 99.63 | -2.13 | -11.50 | 65.43 | 61.67 | 36.52 | 247.48 |
| ROCE % | 18.07% | 16.79% | 12.28% | 39.74% | 9.45% | -3.09% | -4.67% |
This stock is not held by any mutual fund.
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | -5.03 | -1.66 | -2.66 | 11.27 | 1.39 |
| Diluted EPS (Rs.) | -5.03 | -1.66 | -2.66 | 11.27 | 1.39 |
| Cash EPS (Rs.) | -4.56 | -1.21 | -2.23 | 12.13 | 2.20 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 22.63 | 21.64 | 22.98 | 23.93 | 13.55 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 22.63 | 21.64 | 22.98 | 23.93 | 13.55 |
| Revenue From Operations / Share (Rs.) | 22.39 | 35.52 | 45.12 | 64.67 | 55.01 |
| PBDIT / Share (Rs.) | -5.85 | -0.53 | -1.05 | 13.56 | 4.05 |
| PBIT / Share (Rs.) | -6.32 | -0.98 | -1.48 | 12.71 | 3.24 |
| PBT / Share (Rs.) | -6.32 | -1.20 | -4.12 | 12.23 | 2.12 |
| Net Profit / Share (Rs.) | -5.03 | -1.66 | -2.65 | 11.27 | 1.39 |
| NP After MI And SOA / Share (Rs.) | -5.03 | -1.66 | -2.65 | 11.27 | 1.39 |
| PBDIT Margin (%) | -26.13 | -1.50 | -2.33 | 20.97 | 7.37 |
| PBIT Margin (%) | -28.24 | -2.76 | -3.27 | 19.64 | 5.89 |
| PBT Margin (%) | -28.24 | -3.37 | -9.12 | 18.91 | 3.85 |
| Net Profit Margin (%) | -22.46 | -4.67 | -5.88 | 17.42 | 2.52 |
| NP After MI And SOA Margin (%) | -22.46 | -4.67 | -5.88 | 17.42 | 2.52 |
| Return on Networth / Equity (%) | -22.22 | -7.66 | -11.55 | 47.10 | 10.24 |
| Return on Capital Employeed (%) | -27.94 | -4.54 | -6.17 | 41.60 | 15.30 |
| Return On Assets (%) | -19.71 | -4.98 | -9.52 | 27.13 | 3.62 |
| Long Term Debt / Equity (X) | 0.00 | 0.00 | 0.04 | 0.27 | 0.49 |
| Total Debt / Equity (X) | 0.01 | 0.00 | 0.04 | 0.42 | 0.63 |
| Asset Turnover Ratio (%) | 0.76 | 1.16 | 1.30 | 0.03 | 0.04 |
| Current Ratio (X) | 7.24 | 2.10 | 5.01 | 3.44 | 1.30 |
| Quick Ratio (X) | 7.24 | 2.10 | 5.01 | 3.44 | 1.30 |
| Inventory Turnover Ratio (X) | 0.00 | 0.00 | 0.00 | 0.00 | 0.82 |
| Interest Coverage Ratio (X) | 0.00 | -2.49 | -2.49 | 28.74 | 3.61 |
| Interest Coverage Ratio (Post Tax) (X) | 0.00 | -6.70 | -0.03 | 24.89 | 2.24 |
| Enterprise Value (Cr.) | 8.05 | 5.60 | 7.86 | 48.39 | 35.56 |
| EV / Net Operating Revenue (X) | 0.35 | 0.15 | 0.17 | 0.74 | 0.64 |
| EV / EBITDA (X) | -1.36 | -10.36 | -7.39 | 3.53 | 8.68 |
| MarketCap / Net Operating Revenue (X) | 0.46 | 0.41 | 0.31 | 0.81 | 0.60 |
| Price / BV (X) | 0.46 | 0.68 | 0.61 | 2.21 | 2.47 |
| Price / Net Operating Revenue (X) | 0.46 | 0.41 | 0.31 | 0.81 | 0.60 |
| EarningsYield | -0.47 | -0.11 | -0.18 | 0.21 | 0.04 |
After reviewing the key financial ratios for Decipher Labs Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 25, the value is -5.03. This value is below the healthy minimum of 5. It has decreased from -1.66 (Mar 24) to -5.03, marking a decrease of 3.37.
- For Diluted EPS (Rs.), as of Mar 25, the value is -5.03. This value is below the healthy minimum of 5. It has decreased from -1.66 (Mar 24) to -5.03, marking a decrease of 3.37.
- For Cash EPS (Rs.), as of Mar 25, the value is -4.56. This value is below the healthy minimum of 3. It has decreased from -1.21 (Mar 24) to -4.56, marking a decrease of 3.35.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 22.63. It has increased from 21.64 (Mar 24) to 22.63, marking an increase of 0.99.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 22.63. It has increased from 21.64 (Mar 24) to 22.63, marking an increase of 0.99.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 22.39. It has decreased from 35.52 (Mar 24) to 22.39, marking a decrease of 13.13.
- For PBDIT / Share (Rs.), as of Mar 25, the value is -5.85. This value is below the healthy minimum of 2. It has decreased from -0.53 (Mar 24) to -5.85, marking a decrease of 5.32.
- For PBIT / Share (Rs.), as of Mar 25, the value is -6.32. This value is below the healthy minimum of 0. It has decreased from -0.98 (Mar 24) to -6.32, marking a decrease of 5.34.
- For PBT / Share (Rs.), as of Mar 25, the value is -6.32. This value is below the healthy minimum of 0. It has decreased from -1.20 (Mar 24) to -6.32, marking a decrease of 5.12.
- For Net Profit / Share (Rs.), as of Mar 25, the value is -5.03. This value is below the healthy minimum of 2. It has decreased from -1.66 (Mar 24) to -5.03, marking a decrease of 3.37.
- For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is -5.03. This value is below the healthy minimum of 2. It has decreased from -1.66 (Mar 24) to -5.03, marking a decrease of 3.37.
- For PBDIT Margin (%), as of Mar 25, the value is -26.13. This value is below the healthy minimum of 10. It has decreased from -1.50 (Mar 24) to -26.13, marking a decrease of 24.63.
- For PBIT Margin (%), as of Mar 25, the value is -28.24. This value is below the healthy minimum of 10. It has decreased from -2.76 (Mar 24) to -28.24, marking a decrease of 25.48.
- For PBT Margin (%), as of Mar 25, the value is -28.24. This value is below the healthy minimum of 10. It has decreased from -3.37 (Mar 24) to -28.24, marking a decrease of 24.87.
- For Net Profit Margin (%), as of Mar 25, the value is -22.46. This value is below the healthy minimum of 5. It has decreased from -4.67 (Mar 24) to -22.46, marking a decrease of 17.79.
- For NP After MI And SOA Margin (%), as of Mar 25, the value is -22.46. This value is below the healthy minimum of 8. It has decreased from -4.67 (Mar 24) to -22.46, marking a decrease of 17.79.
- For Return on Networth / Equity (%), as of Mar 25, the value is -22.22. This value is below the healthy minimum of 15. It has decreased from -7.66 (Mar 24) to -22.22, marking a decrease of 14.56.
- For Return on Capital Employeed (%), as of Mar 25, the value is -27.94. This value is below the healthy minimum of 10. It has decreased from -4.54 (Mar 24) to -27.94, marking a decrease of 23.40.
- For Return On Assets (%), as of Mar 25, the value is -19.71. This value is below the healthy minimum of 5. It has decreased from -4.98 (Mar 24) to -19.71, marking a decrease of 14.73.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 0.2. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.01. This value is within the healthy range. It has increased from 0.00 (Mar 24) to 0.01, marking an increase of 0.01.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.76. It has decreased from 1.16 (Mar 24) to 0.76, marking a decrease of 0.40.
- For Current Ratio (X), as of Mar 25, the value is 7.24. This value exceeds the healthy maximum of 3. It has increased from 2.10 (Mar 24) to 7.24, marking an increase of 5.14.
- For Quick Ratio (X), as of Mar 25, the value is 7.24. This value exceeds the healthy maximum of 2. It has increased from 2.10 (Mar 24) to 7.24, marking an increase of 5.14.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 4. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 3. It has increased from -2.49 (Mar 24) to 0.00, marking an increase of 2.49.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 3. It has increased from -6.70 (Mar 24) to 0.00, marking an increase of 6.70.
- For Enterprise Value (Cr.), as of Mar 25, the value is 8.05. It has increased from 5.60 (Mar 24) to 8.05, marking an increase of 2.45.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 0.35. This value is below the healthy minimum of 1. It has increased from 0.15 (Mar 24) to 0.35, marking an increase of 0.20.
- For EV / EBITDA (X), as of Mar 25, the value is -1.36. This value is below the healthy minimum of 5. It has increased from -10.36 (Mar 24) to -1.36, marking an increase of 9.00.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 0.46. This value is below the healthy minimum of 1. It has increased from 0.41 (Mar 24) to 0.46, marking an increase of 0.05.
- For Price / BV (X), as of Mar 25, the value is 0.46. This value is below the healthy minimum of 1. It has decreased from 0.68 (Mar 24) to 0.46, marking a decrease of 0.22.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 0.46. This value is below the healthy minimum of 1. It has increased from 0.41 (Mar 24) to 0.46, marking an increase of 0.05.
- For EarningsYield, as of Mar 25, the value is -0.47. This value is below the healthy minimum of 5. It has decreased from -0.11 (Mar 24) to -0.47, marking a decrease of 0.36.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Decipher Labs Ltd:
- Net Profit Margin: -22.46%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: -27.94% (Industry Average ROCE: 16.29%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: -22.22% (Industry Average ROE: 15.2%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 0
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 7.24
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 0 (Industry average Stock P/E: 51.46)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.01
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: -22.46%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Pharmaceuticals | A-2, Q2, 5th Floor, Cyber Towers, Hyderabad Telangana 500081 | cs@decipherlabs.in http://www.decipherlabs.in |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Sushant Mohan Lal | Non Executive Director |
| Mr. G Venkateswara Rao | Independent Director |
| Mrs. Lakshmi Vijaya Nimmala | Independent Director |
| Mrs. Gayathri Raghuram | Independent Director |
| Mr. Janaki Ram Ajjarapu | Non Executive Director |
FAQ
What is the intrinsic value of Decipher Labs Ltd?
Decipher Labs Ltd's intrinsic value (as of 17 December 2025) is 2.70 which is 71.88% lower the current market price of 9.60, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's 9.70 Cr. market cap, FY2025-2026 high/low of 17.2/9.00, reserves of ₹9.04 Cr, and liabilities of 23.76 Cr.
What is the Market Cap of Decipher Labs Ltd?
The Market Cap of Decipher Labs Ltd is 9.70 Cr..
What is the current Stock Price of Decipher Labs Ltd as on 17 December 2025?
The current stock price of Decipher Labs Ltd as on 17 December 2025 is 9.60.
What is the High / Low of Decipher Labs Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Decipher Labs Ltd stocks is 17.2/9.00.
What is the Stock P/E of Decipher Labs Ltd?
The Stock P/E of Decipher Labs Ltd is .
What is the Book Value of Decipher Labs Ltd?
The Book Value of Decipher Labs Ltd is 19.0.
What is the Dividend Yield of Decipher Labs Ltd?
The Dividend Yield of Decipher Labs Ltd is 0.00 %.
What is the ROCE of Decipher Labs Ltd?
The ROCE of Decipher Labs Ltd is 4.67 %.
What is the ROE of Decipher Labs Ltd?
The ROE of Decipher Labs Ltd is 1.16 %.
What is the Face Value of Decipher Labs Ltd?
The Face Value of Decipher Labs Ltd is 10.0.